Gene therapy of fibroproliferative vasculopathies: Current ideas in molecular mechanisms and biomedical technology

Pharmacogenomics

Volumn 7, Issue 8, 2006, Pages 1185-1198

  Mitra, Amit K ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bypass grafts; Gene therapy; Proliferation; Restenosis; Saphenous vein; Smooth muscle cells; Viral vectors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOPOIETIN 1; ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; CARDIOVASCULAR AGENT; CYCLIN DEPENDENT KINASE 1; CYCLINE; EDIFOLIGIDE; GENE PRODUCT; HIRUDIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; NAKED DNA; PLACEBO; PLASMID DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BB; POLYMER; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR E2F; VASCULOTROPIN A;

ABSENCE OF SIDE EFFECTS; ADENOVIRUS VECTOR; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CATHETERIZATION; CELL PROTECTION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG POTENTIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN-STENT RESTENOSIS; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VEIN GRAFT DISEASE;

BIOMEDICAL TECHNOLOGY; CORONARY RESTENOSIS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; TUNICA INTIMA;

ANIMALIA;

EID: 33845866638     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.8.1185     Document Type: Review

References (97)

1. Bennett MR, O'Sullivan M: Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol. Ther. 91, 149-166 (2001).
2. Chandrasekar B, Tanguay JF: Platelets and restenosis. J. Am. Coll. Cardiol. 35, 555-562 (2000).
3. Rasmussen LM, Wolf YG, Ruoslahti E: Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-β activity. Am J Pathol. 147, 1041-1048 (1995).
4. Schwartz SM, Campbell GR, Campbell JH: Replication of smooth muscle cells in vascular disease. Circ. Res. 58, 427-444 (1986).
5. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90, 251-262 (2002).
6. Strauss BH, Robinson R, Batchelor WB et al.: In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ. Res. 79, 541-550 (1996).
7. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75, 539-545 (1994).
8. Raugi GJ, Mullen JS, Bark DH, Okada T, Mayberg MR: Thrombospondin deposition in rat carotid artery injury. Am J. Pathol. 137, 179-185 (1990).
9. Riessen R, Wight TN, Pastore C, Henley C, Isner JM: Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 93, 1141-1147 (1996).
10. Sibinga NE, Foster LC, Hsieh CM et al.: Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury. Circ. Res. 80, 532-541 (1997).
11. Karim MA, Miller DD, Farrar MA et al.: Histomorphometric and biochemical correlates of arterial procollagen gene expression during vascular repair after experimental angioplasty. Circulation 91, 2049-2057 (1995).
12. Mintz GS, Popma JJ, Pichard AD et al.: Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94, 35-43 (1996).
13. Davies MG, Hagen PO: Pathophysiology of vein graft failure: a review. Eur. J. Vasc. Endovasc. Surg. 9, 7-18 (1995).
14. Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97, 916-931 (1998).
15. Shi Y, O'Brien JE Jr, Fard A, Zalewski A: Transforming growth factor-β 1 expression and myofibroblast formation during arterial repair. Arterioscler. Thromb. Vasc. Biol. 16, 1298-1305 (1996).
16. Shi Y, JE O'Brien, Fard A, Mannion JD, Wang D, Zalewski A: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94, 1655-1664 (1996).
17. Schwartz RS, Chronos NA, Virmani R: Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J. Am. Coll. Cardiol. 44, 1373-1385 (2004).
18. Lafont A, Guzman LA, Whitlow PL, Goormastic, M, Cornhill JF, Chisolm GM: Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ. Res. 76, 996-1002 (1995).
19. Hermans WR, Rensing BJ, Strauss BH, Serruys PW: Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a 'magic bullet'. Am. Heart J. 122, 171-187 (1991).
20. Muller DW, Ellis SG, Topol EJ: Experimental models of coronary artery restenosis. J. Am. Coll. Cardlol. 19, 418-432 (1992).
21. Schwartz RS, Huber KC, Murphy JG et al.: Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J. Am. Coll. Cardiol. 19, 267-274 (1992).
22. Channon KM, Fulton GJ, Gray JL et al.: Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc. Res. 35, 505-513 (1997).
23. Kupfer JM, Ruan XM, Liu G, Matloff J, Forrester J, Chaux A: High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. 5, 1437-1443 (1994).
24. Stevenson AJ, Cooper M, Griffiths JC et al.: Assessment of Herpesvirus saimiri as a potential human gene therapy vector. J. Med. Virol. 57, 269-277 (1999).
25. Bergelson JM: Receptors mediating adenovirus attachment and internalization. Biochem. Pharmacol. 57, 975-979 (1999).
26. Biermann V, Voipers C, Hussmann S et al: Targeting of high-capacity adenoviral vectors. Hum. Gene. Ther. 12, 1757-1769 (2001).
27. Hiltunen MO, Turtmen MP, Turunen AM et al.: Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J. 14, 2230-2236 (2000).
28. Laukkanen MO, Kivela A, Rissanen T et al.: Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 106, 1999-2003 (2002).
29. Summerford C, Bartlett JS, Samulski RJ: αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82 (1999).
30. Snyder RO, Spratt SK, Lagarde C et al.: Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Cene. Ther. 8, 1891-1900 (1997).
31. Dong JY, Fan PD, Frizzen RA: Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene. Aer. 7, 2101-2112 (1996).
32. Miller AD: Retroviral vectors. Curr. Top Microbiol. Immunol. 158, 1-24 (1992).
33. Debyser Z: Biosafety of lentiviral vectors. Curr. Gene THer. 3, 517-525 (2003).
34. Yanez-Munoz RJ, Balaggan KS, MacNeil A et al.: Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348-353 (2006).
35. Huser A, Hofmann C: Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications. Am. J. Pharmacogenomics. 3, 53-63 (2003).
36. Dzau VJ, Mann MJ, Morishita R, Kaneda Y: Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl Acad. Sci. USA 93, 11421-11425 (1996).
37. Niidome T, Huang L: Gene therapy progress and prospectc nonviral vectors. Gene Ther. 9, 1647-1652 (2002).
38. Turunen MP, Hiltunen MO, Ruponen M et al.: Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Cene ther. 6, 6-11 (1999).
39. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70 (1992).
40. Morishita R, Gibbons GH, Ellison KE et al.: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl Acad. Sci. USA 90, 8474-8478 (1993).
41. Kutryk MJ, Foley DP, van den BM et al: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. 39, 281-287 (2002).
42. Mann MJ, Whittemore AD, Donaldson MC et al.: Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354, 1493-1498 (1999).
43. Grube E, FelderhoffT, Fitzgerald PJ et al.: Genetic manipulation of human coronary artery bypass grafts with E2F decoy (GT003) reduces clinical graft failure: Results of the randomized, controlled PREVENT II Trial [abstract]. American Heart Association Annual Meeting: late breaking clinical trials. Anaheim, CA, USA. Circulation 104, 1b (2001)
44. Conte MS, Bandyk DF, Clowes AW et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43, 742-751 (2006).
45. Alexander JH, Hafley G, Harrington RA et al.: Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294, 2446-2454 (2005).
46. Fechner H, Haack A, Wang H et al.: Expression of coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520-1535 (1999).
47. Hiltunen MO, Turunen MP, Turunen AM et al.: Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J. 14, 2230-2236 (2000).
48. Hata JA, Petrofski JA, Schroder JN et al.: Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J. Thorac. Cardiovasc. Surg. 129, 1405-1413 (2005).
49. Du X, Yang Y, Le VC et al.: In vivo US monitoring of catheter-based vascular delivery of gene microspheres in pigs: feasibility. Radiology 228, 555-559 (2003).
50. Breuss JM, Cejna M, Bergmeister H et al.: Activation of nuclear factor-κB significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Cirrulation 105, 633-638 (2002).
51. Miller DL, Pislaru SV, Greenleaf JE: Sonoporation: mechanical DNA delivery by ultrasonic cavitation. Somat. Cell Mol. Genet. 27, 115-134 (2002).
52. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME: Ultrasound-mediated transfection of mammalian cells. Hum. Gene. Ther. 7, 1339-1346 (1996).
53. Yamashita Y, Shimada M, Tachibana K et al.: In vivo gene transfer into muscle via electro-sonoporation. Hum. Gene. Ther. 13, 2079-2084 (2002).
54. Taniyama Y, Tachibana K, Hiraoka K et al.: Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 105, 1233-1239 (2002).
55. Yamasaki K, Asai T, Shimizu M et al.: Inhibition of NFκB activation using cis-element 'decoy' of NFκB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther. 10, 356-364 (2003).
56. Yoshimura S, Morishita R, Hayashi K et al.: Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-κB binding site as a novel molecular strategy. Gene Ther. 8, 1635-1642 (2001).
57. Inagaki H, Suzuki J, Ogawa M, Taniyama Y, Morishita R, Isobe M: Ultrasound-microbubble-mediated NF-κB decoy transfection attenuates neointimal formation after arterial injury in mice. J. Vasc. Res. 43, 12-18 (2006).
58. Kankkonen HM, Turunen MP, Hiltunen MO et al.: Feline immunodeficiency virus and retrovirus-mediated adventitial ex vivo gene transfer to rabbit carotid artery using autologous vascular smooth muscle cells. J. Mol. Cell Cardiol. 36, 333-341 (2004).
59. Grossman M, Rader DJ, Muller DW et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. 1, 1148-1154 (1995).
60. Forough R, Koyama N, Hasenstab D et al.: Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res. 79, 812-820 (1996).
61. Dishart KL, Work LM, Denby L, Baker AH: Gene therapy for cardiovascular disease. J. Biomed. Biotechnol. 2003, 138-148 (2003).
62. Abendschein DR, Recchia D, Meng YY et al.: Inhibition of thrombin attenuates stenosis after arterial injury in minipigs. J. Am. Coll. Cardlol. 28, 1849-1855 (1996).
63. Rade JJ, Schulick AH, Virmani R, Dichek DA: Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat. Med. 2, 293-298 (1996).
64. Atsuchi N, Nishida T, Marutsuka K et al.: Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 103, 570-575 (2001).
65. Yin X, Yutani C, Ikeda Y et al.: Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc. Res. 56, 454-463 (2002).
66. Satoh K, Takamatsu S, Imaizumi T et al.: Endothelial injury as an initiating factor: vascular endothelial cell injury and biosynthesis of PAF. Nippon Rinsho 46, 552-557 (1988).
67. Quarck R, De GB, Stengel D, Mertens A et al.: Adenovirus-mediated gene transfer of human platelet-activating factor-acetythydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103, 2495-2500 (2001).
68. Nikkari ST, Hoyhtya M, J Isola, Nikkari T: Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J. Pathol. 149, 1427-1433 (1996).
69. Brew K, D Dinakarpandian, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283 (2000).
70. Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR: Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 99, 3199-3205 (1999).
71. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum. Gene. Ther. 9, 867-877 (1998).
72. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH: Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101, 296-304 (2000).
73. Guo YH, Gao W, Li Q, Li PF, Yao PY, Chen K: Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell irdgration and induces cell apoptosis. Life Sci. 75, 2483-2493 (2004).
74. Hasenstab D, H Lea and Clowes AW: Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler. Thromb. Vasc. Biol. 20, 853-859 (2000).
75. Varenne O, Sinnaeve P, Gillijns H et al.: Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum. Gene. Ther. 11, 1329-1339 (2000).
76. Ascher E, Scheinman M, Hingorani A, Seth P, Marella VK, Jacob T. Effect of p53 gene therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model. Ann Vasc Surg 14, 385-392 (2000).
77. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andres V: Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99, 2334-2341 (1997).
78. Huehns TY, Krausz E, Mrochen S et al.: Neointimal growth can be influenced by local adventitial gene manipulation via a needle injection catheter. Atheresclerosis 144, 135-150 (1999).
79. Luo Z, Sata M, Nguyen T, Kaplan JM, Akita GY, Walsh K: Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 99, 1776-1779 (1999).
80. Smith E, Frenkel B, MacLachlan TK et al.: Post-proliferative cyclin E-associated kinase activity in differentiated osteoblasts: inhibition by proliferating osteoblasts and osteosarcoma cells. J. Cell. Biochem. 66, 141-152 (1997).
81. Duckers HJ, Boehm M, True AL et al.: Heme oxygenase-1 protects against vascular constriction and proliferation. Nat. Med. 7, 693-698 (2001).
82. Mano T, Luo Z, Malendowicz SL, Evans T, Walsh K: Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ. Res. 84, 647-654 (1999).
83. Indolfi C, Avvedimento EV, Rapacciuolo A et al.: In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase kinase. Basic Res. Cardiol. 92, 378-384 (1997).
84. Izumi Y, Kim S, Namba M et al.: Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ. Res. 88, 1120-1126 (2001).
85. Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A: Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arteriosler. Thromb. Vasc. Biol. 17, 898-904 (1997).
86. Ferrara N: Vascular endothelial growth factor. Eur. J. Cancer 32A, 2413-2422 (1996).
87. Hiltunen MO, Laitinen M, Turunen MP et al: Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 102, 2262-2268 (2000).
88. Walter DH, Cejna M, az-Sandoval L et al.: Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110, 36-45 (2004).
89. Rutanen J, Markkanen J, Yla-Herttuala S: Gene therapy for restenosis: current status. Drugs 62, 1575-1585 (2002).
90. Hedman M, Hartikainen J, Syvanne M et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuoplo Angiogenesis Trial (KAT). Circulation 107, 2677-2683 (2003).
91. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Ann. Rev. Immunol. 18, 217-242 (2000).
92. Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ: Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J. Biol. Cbem. 277, 2785-2789 (2002).
93. Bursill CA, Cai S, Channon KM, Greaves DR: Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo. Immunobiology 207, 187-196 (2003).
94. Siddiqui AJ, Blomberg P, Wardell E et al.: Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem. Biophys. Res. Commun. 310, 1002-1009 (2003).
95. Hao X, A Mansson-Broberg, Gustafsson T et al.: Angiogenic effects of dual gene transfer of bFGF and PDGF-BB after myocardial infarction. Biochem. Biophys. Res. Commun. 315, 1058-1063 (2004).
96. Amalfitano A, Parks RJ: Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr. Gene Ther. 2, 111-133 (2002).
97. Mitani K, Kubo, S: Adenovirus as an integrating vector. Curr. Gene Ther. 2, 135-144 (2002).